期刊
CURRENT OPINION IN PHARMACOLOGY
卷 59, 期 -, 页码 33-42出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2021.04.004
关键词
PRMTs; MTAP; Splicing factor mutations
资金
- National Cancer Institute of the NIH [R01 CA249204, R01CA248984]
- ISMMS seed fund
- NCI training grant [T32CA078207]
Protein arginine methylation plays a crucial role in regulating cellular processes, and significant progress has been made in the development of molecular tools and clinical compounds to inhibit PRMT functions. Studies have shown that somatic mutations in cancer cells can create vulnerabilities that can be exploited through PRMT inhibition. Additionally, research has identified synthetic lethal combinations between existing therapies and PRMT inhibitors.
Protein arginine methylation is an abundant post-translational modification involved in the modulation of essential cellular processes ranging from transcription, post-transcriptional RNA metabolism, and propagation of signaling cascades to the regulation of the DNA damage response. Excitingly for the field, in the past few years there have been remarkable advances in the development of molecular tools and clinical compounds able to selectively and potently inhibit protein arginine methyltransferase (PRMT) functions. In this review, we first discuss how the somatic mutations that confer advantages to cancer cells are often associated with vulnerabilities that can be exploited by PRMTs' inhibition. In a second part, we discuss strategies to uncover synthetic lethal combinations between existing therapies and PRMT inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据